206 related articles for article (PubMed ID: 32621557)
1. Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial.
McAlister FA; Zheng Y; Westerhout CM; Buse JB; Standl E; McGuire DK; Van de Werf F; Green JB; Armstrong PW; Holman RR;
Eur J Heart Fail; 2020 Nov; 22(11):2026-2034. PubMed ID: 32621557
[TBL] [Abstract][Full Text] [Related]
2. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
Shavadia JS; Zheng Y; Green JB; Armstrong PW; Westerhout CM; McGuire DK; Cornel JH; Holman RR; Peterson ED
Am Heart J; 2019 Dec; 218():92-99. PubMed ID: 31715435
[TBL] [Abstract][Full Text] [Related]
3. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
McGuire DK; Van de Werf F; Armstrong PW; Standl E; Koglin J; Green JB; Bethel MA; Cornel JH; Lopes RD; Halvorsen S; Ambrosio G; Buse JB; Josse RG; Lachin JM; Pencina MJ; Garg J; Lokhnygina Y; Holman RR; Peterson ED;
JAMA Cardiol; 2016 May; 1(2):126-35. PubMed ID: 27437883
[TBL] [Abstract][Full Text] [Related]
4. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Green JB; Bethel MA; Armstrong PW; Buse JB; Engel SS; Garg J; Josse R; Kaufman KD; Koglin J; Korn S; Lachin JM; McGuire DK; Pencina MJ; Standl E; Stein PP; Suryawanshi S; Van de Werf F; Peterson ED; Holman RR;
N Engl J Med; 2015 Jul; 373(3):232-42. PubMed ID: 26052984
[TBL] [Abstract][Full Text] [Related]
5. Association Between Type 2 Diabetes and All-Cause Hospitalization and Mortality in the UK General Heart Failure Population: Stratification by Diabetic Glycemic Control and Medication Intensification.
Lawson CA; Jones PW; Teece L; Dunbar SB; Seferovic PM; Khunti K; Mamas M; Kadam UT
JACC Heart Fail; 2018 Jan; 6(1):18-26. PubMed ID: 29032131
[TBL] [Abstract][Full Text] [Related]
6. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
Nauck MA; McGuire DK; Pieper KS; Lokhnygina Y; Strandberg TE; Riefflin A; Delibasi T; Peterson ED; White HD; Scott R; Holman RR
Cardiovasc Diabetol; 2019 Sep; 18(1):116. PubMed ID: 31481069
[TBL] [Abstract][Full Text] [Related]
7. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
[TBL] [Abstract][Full Text] [Related]
8. Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical Trials.
Marx N; Kolkailah AA; Rosenstock J; Johansen OE; Cooper ME; Alexander JH; Toto RD; Wanner C; Espeland MA; Mattheus M; Schnaidt S; Perkovic V; Gollop ND; McGuire DK
JAMA Cardiol; 2024 Feb; 9(2):134-143. PubMed ID: 38170502
[TBL] [Abstract][Full Text] [Related]
9. Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).
Pagidipati NJ; Navar AM; Pieper KS; Green JB; Bethel MA; Armstrong PW; Josse RG; McGuire DK; Lokhnygina Y; Cornel JH; Halvorsen S; Strandberg TE; Delibasi T; Holman RR; Peterson ED;
Circulation; 2017 Sep; 136(13):1193-1203. PubMed ID: 28626088
[TBL] [Abstract][Full Text] [Related]
10. Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS.
Pagidipati NJ; Zheng Y; Green JB; McGuire DK; Mentz RJ; Shah S; Aschner P; Delibasi T; Rodbard HW; Westerhout CM; Holman RR; Peterson ED;
Am Heart J; 2020 Jan; 219():47-57. PubMed ID: 31707324
[TBL] [Abstract][Full Text] [Related]
11. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
Green JB; Bethel MA; Paul SK; Ring A; Kaufman KD; Shapiro DR; Califf RM; Holman RR
Am Heart J; 2013 Dec; 166(6):983-989.e7. PubMed ID: 24268212
[TBL] [Abstract][Full Text] [Related]
12. Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.
Alfredsson J; Green JB; Stevens SR; Reed SD; Armstrong PW; Angelyn Bethel M; Engel SS; McGuire DK; Van de Werf F; Hramiak I; White HD; Peterson ED; Holman RR;
Diabetes Obes Metab; 2018 Oct; 20(10):2379-2388. PubMed ID: 29923323
[TBL] [Abstract][Full Text] [Related]
13. Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.
Standl E; Stevens SR; Armstrong PW; Buse JB; Chan JCN; Green JB; Lachin JM; Scheen A; Travert F; Van de Werf F; Peterson ED; Holman RR;
Diabetes Care; 2018 Mar; 41(3):596-603. PubMed ID: 29311155
[TBL] [Abstract][Full Text] [Related]
14. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Bethel MA; Engel SS; Green JB; Huang Z; Josse RG; Kaufman KD; Standl E; Suryawanshi S; Van de Werf F; McGuire DK; Peterson ED; Holman RR;
Diabetes Care; 2017 Apr; 40(4):494-501. PubMed ID: 28057693
[TBL] [Abstract][Full Text] [Related]
15. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.
Josse RG; Majumdar SR; Zheng Y; Adler A; Bethel MA; Buse JB; Green JB; Kaufman KD; Rodbard HW; Tankova T; Westerhout CM; Peterson ED; Holman RR; Armstrong PW;
Diabetes Obes Metab; 2017 Jan; 19(1):78-86. PubMed ID: 27607571
[TBL] [Abstract][Full Text] [Related]
16. Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial.
Sharma A; Green JB; Dunning A; Lokhnygina Y; Al-Khatib SM; Lopes RD; Buse JB; Lachin JM; Van de Werf F; Armstrong PW; Kaufman KD; Standl E; Chan JCN; Distiller LA; Scott R; Peterson ED; Holman RR;
Diabetes Care; 2017 Dec; 40(12):1763-1770. PubMed ID: 28986504
[TBL] [Abstract][Full Text] [Related]
17. Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.
Menon V; Kumar A; Patel DR; John JS; Wolski KE; McErlean E; Riesmeyer JS; Weerakkody G; Ruotolo G; Cremer PC; Nicholls SJ; Lincoff AM; Nissen SE
J Am Heart Assoc; 2020 Jan; 9(1):e014328. PubMed ID: 31852422
[TBL] [Abstract][Full Text] [Related]
18. Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: Evidence from meta-regression analysis of randomized controlled trials.
Huang CJ; Wang WT; Sung SH; Chen CH; Lip GYH; Cheng HM; Chiang CE
Diabetes Obes Metab; 2018 Sep; 20(9):2131-2139. PubMed ID: 29722116
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
Green JB; Everett BM; Ghosh A; Younes N; Krause-Steinrauf H; Barzilay J; Desouza C; Inzucchi SE; Pokharel Y; Schade D; Scrymgeour A; Tan MH; Utzschneider KM; Mudaliar S;
Circulation; 2024 Mar; 149(13):993-1003. PubMed ID: 38344820
[TBL] [Abstract][Full Text] [Related]
20. Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
Bethel MA; Sourij H; Stevens SR; Hannan K; Lokhnygina Y; Adler AI; Peterson ED; Holman RR; Lopes RD
Cardiovasc Diabetol; 2023 Mar; 22(1):72. PubMed ID: 36978066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
